Preparation of dendrimer polyol/mesoporous silica nanocomposite for reversible CO₂ adsorption: Effect of pore size and polyol content

<p>This paper focuses on the synthesis of polyol/MCM-48 nanocomposite materials with different percentages of polyalcohol dendrimer H20. The obtained materials were used for CO₂ adsorption. CO₂-TPD analysis showed that the samples containing 1 and 3 wt% of H20 dendrimer have low CO₂ adsorption capacity due to the occupation of active sites, The sample prepared with 0.5 wt% of H20 dendrimer exhibited higher adsorption capacity and thermal stability. The affinity toward CO₂ was found to be mainly due to the presence of organic moiety within the MCM-48 pores.</p

The Lymphoid Variant of Hypereosinophilic Syndrome

International audienc

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

International audienc

Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up

International audienceAbstract In total, 279 patients with hairy-cell leukemia (HCL) were analyzed, with a median follow-up of 10 years. Data were collected up to June 2018. We analyzed responses to treatment, relapses, survival, and the occurrence of second malignancies during follow-up. The median age was 59 years. In total, 208 patients (75%) were treated with purine analogs (PNAs), either cladribine (159) or pentosatin (49), as the first-line therapy. After a median follow-up of 127 months, the median overall survival was 27 years, and the median relapse-free survival (RFS) was 11 years. The cumulative 10-year relapse incidence was 39%. In patients receiving second-line therapy, the median RFS was 7 years. For the second-line therapy, using the same or another PNA was equivalent. We identified 68 second malignancies in 59 patients: 49 solid cancers and 19 hematological malignancies. The 10-year cumulative incidences of cancers, solid tumors, and hematological malignancies were 15%, 11%, and 5.0%, respectively, and the standardized incidence ratios were 2.22, 1.81, and 6.67, respectively. In multivariate analysis, PNA was not a risk factor for second malignancies. HCL patients have a good long-term prognosis. PNAs are the first-line treatment. HCL patients require long-term follow-up because of their relatively increased risk of second malignancies

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

International audienc